Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Sreedharanunni S, Varma N, Sachdeva MUS et al (2018) The spectrum of hypereosinophilia and associated clonal disorders—a real-world data based on combined retrospective and prospective analysis from a tropical setting. Mediterr J Hematol Infect Dis 10:e2018052. https://doi.org/10.4084/MJHID.2018.052
2. Bain BJ, Horny HP, Arber DA, Tefferi A, Hasserjian RP (2017) Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 72–79
3. Gotlib J, Cools J (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22:1999–2010. https://doi.org/10.1038/leu.2008.287
4. Srinivas U, Barwad A, Pubbaraju SV (2014) Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy. Br J Haematol 165:583. https://doi.org/10.1111/bjh.12742
5. Kumar AN, Sathyanarayanan V, Devi VL et al (2014) FIP1L1-PDGFRA-positive chronic eosinophilic leukemia: a low-burden disease with dramatic response to imatinib—a report of 5 cases from South India. Turk J Haematol 31:56–60. https://doi.org/10.4274/Tjh.2013.0086
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献